We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Physiological Status Unaffected by Blood Storage Duration

By LabMedica International staff writers
Posted on 07 Feb 2012
Print article
Alterations to both red blood cells (RBC) and their media during the storage process are potentially responsible for many of the adverse effects associated with RBC administration.

The impact of RBC storage duration has been evaluated on short-term pulmonary function and immunologic status in mechanically ventilated patients receiving RBC transfusion.

Scientists at the Mayo Clinic (Rochester, MN, USA) conducted a double-blind trial, where 50 patients were randomized to receive fresh RBC with a median storage duration of four days and 50 patients were randomized to receive standard issue RBC with a median storage duration of 26.5 days. All RBC units underwent prestorage leukoreduction. All the patients were mechanically ventilated in the intensive care unit (ICU).

The primary outcome measure of change was in pulmonary function arterial oxygen tension - fractional inspired oxygen (PaO2/FiO2) ratio. Other outcome measures included the immunologic status by estimating levels of tumor necrosis factor-alpha, interleukin-8, C-reactive protein and the coagulation status by measuring fibrinogen, anti-thrombin consumption. Measurements were obtained at baseline and within two hours of the completion of RBC transfusion.

No significant differences between groups were seen in the primary outcome measure of change in PaO2/FiO2 ratio: fresh RBC was 2.5 ± 49.3 and standard issue RBC was -9.0 ± 69.8. Similarly, no significant differences were seen for any of the other outcome measures of pulmonary function such as fraction of dead space ventilation, dynamic and static pulmonary compliance or the immunologic and coagulation status measurements.

Daryl J. Kor, MD, assistant professor of anesthesiology at the Mayo Clinic College of Medicine, said, "Our data do not support a significant effect of RBC storage duration on respiratory, immunologic or coagulation parameters in the immediate posttransfusion period. Previous observational studies linking RBC storage duration and respiratory complications may have suffered from bias and unmeasured confounding, which were more effectively addressed in our double-blind, randomized trial study design." The study was published online on January 26, 2012 in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
Mayo Clinic



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.